ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Kyowa Kirin Co., Ltd.

Business Summary

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. It also produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2021 JPYUSD
Gross Profit253,894M2,310.79M
Operating income61,110M556.18M
Income before tax55,475M504.90M
Net income52,347M476.43M
Diluted EPS97.380.88
Dividends Per Share460.41
Total Assets921,872M8,005.48M
Total liabilities184,710M1,604.01M
Total equity737,162M6,401.47M
Operating cash flow86,548M787.70M
Currency in JPYCurrency in USD

Historical Data

 Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021
Revenue 353,380M 271,510M 305,820M 318,352M 352,246M
Gross Profit 215,972M 188,834M 215,129M 227,827M 253,894M
Operating income 62,209M 50,403M 53,354M 55,419M 61,110M
Income before tax 55,849M 66,841M 44,492M 52,263M 55,475M
Net income 42,899M 49,230M 37,674M 47,027M 52,347M
EBITDA 84,241M 66,646M 72,151M 75,885M 80,608M
Diluted EPS 78.30 99.29 43.12 87.49 97.38
Dividends Per Share 27 35 42 44 46
Total Assets 708,295M 741,982M 784,453M 801,290M 921,872M
Total liabilities 92,268M 92,589M 106,203M 102,893M 184,710M
Total equity 616,028M 649,621M 678,250M 698,396M 737,162M
Operating cash flow 64,902M 56,181M 53,655M 39,502M 86,548M
 Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021
Revenue 3,151.41M 2,458.37M 2,805.40M 2,981.70M 3,205.93M
Gross Profit 1,926.02M 1,709.78M 1,973.46M 2,133.84M 2,310.79M
Operating income 554.77M 456.37M 489.43M 519.05M 556.18M
Income before tax 498.05M 605.20M 408.14M 489.49M 504.90M
Net income 382.57M 445.75M 345.59M 440.45M 476.43M
EBITDA 751.25M 603.44M 661.87M 710.74M 733.64M
Diluted EPS 0.69 0.89 0.39 0.81 0.88
Dividends Per Share 0.24 0.31 0.38 0.41 0.41
Total Assets 6,287.57M 6,762.81M 7,218.33M 7,761.05M 8,005.48M
Total liabilities 819.06M 843.90M 977.25M 996.59M 1,604.01M
Total equity 5,468.51M 5,920.98M 6,241.08M 6,764.45M 6,401.47M
Operating cash flow 578.79M 508.68M 492.19M 369.97M 787.70M

Valuation Measures

Dec 2021
Operating margin17.34%
Profit margin14.86%

Key executives

  • President, CEO & Representative Director: Masashi Miyamoto
  • Executive Officer, Manager-Accounting & Finance: Motohiko Kawaguchi
  • Executive Officer, GM-Research & Development: Mitsuo Satoh
  • Representative Director & Executive Vice President: Yutaka Osawa
  • Executive Officer & General Manager-Sales: Hiroshi Sugitani


  • Kirin Holdings Co., Ltd. (53.4%)
  • Nomura Asset Management Co., Ltd. (3.5%)
  • Daiwa Asset Management Co. Ltd. (1.6%)
  • Nikko Asset Management Co., Ltd. (1.6%)
  • Massachusetts Financial Services Co. (1.4%)
  • The Vanguard Group, Inc. (1.1%)
  • BlackRock Fund Advisors (0.9%)
  • Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.8%)
  • Norges Bank Investment Management (0.6%)
  • JPMorgan Asset Management (UK) Ltd. (0.5%)

Contact Details

  • Website:
  • Address: Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Tokyo, 100-0004, Japan
  • Phone: +81.3.5205.7200

Related Companies

  • Kyowa Kirin Australia Pty Ltd.
  • Kyowa Kirin Pharma FZ LLC
  • Kyowa Kirin Malaysia Sdn. Bhd.
  • Kyowa Kirin Korea Co., Ltd.
  • Kyowa Kirin Pharma SRL
  • Kyowa Kirin Pharma sro
  • Kyowa Kirin Austria GmbH
  • Kyowa Kirin SARL
  • Kyowa Kirin AB
  • Kyowa Kirin Pharma BV
  • Kyowa Kirin Holdings BV
  • Kyowa Kirin Farmaceutica SL
  • Kyowa Kirin Ireland Ltd.
  • Kyowa Kirin Canada, Inc.
  • Kyowa Kirin Frontier Co., Ltd.
  • Kyowa Medical Promotion Co., Ltd.
  • Kyowa Kirin GmbH
  • Strakan International SARL
  • Kyowa Kirin Plus Co., Ltd.
  • Kyowa Hakko Bio Co. Ltd. (Beijing)
  • Kyowa Hakko Bio (Shanghai) Trading Co., Ltd.
  • Kyowa Hakko Bio (Shanghai) Trading Co. Ltd. /Beijing Branch/
  • Kyowa Hakko Bio Shanghai Trading Co. Ltd. /Guangzhou/
  • Kyowa Hakko Kirin (Hong Kong) Co. Ltd.
  • Kyowa Hakko Kirin (Taiwan) Co. Ltd.
  • Kyowa Hakko Kirin (Singapore) Pte Ltd.
  • Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin (Thailand) Co. Ltd.
  • ProStrakan SRL
  • Kyowa Hakko Kirin America, Inc.


  • Genexine, Inc.
  • Innate Pharma SA Class A
  • FibroGen, Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Springworks Therapeutics, Inc.
  • Tetralogic Pharmaceuticals Corporation
  • Citius Pharmaceuticals Inc
  • Ikena Oncology, Inc.
  • Seagen, Inc.
  • Heron Therapeutics Inc
  • Prometheus Biosciences, Inc
Last Updated on 18 May, 2022

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more